Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders.
- Published In:
- European journal of medicinal chemistry, 305, 118587 (2026)
- Database ID:
- RPEP-14732
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14732APA
Alavi, Seyed Ebrahim; Boshrouyeh, Reza; Raza, Aun; Ebrahimi Shahmabadi, Hasan. (2026). Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders.. European journal of medicinal chemistry, 305, 118587. https://doi.org/10.1016/j.ejmech.2026.118587
MLA
Alavi, Seyed Ebrahim, et al. "Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders.." European journal of medicinal chemistry, 2026. https://doi.org/10.1016/j.ejmech.2026.118587
RethinkPeptides
RethinkPeptides Research Database. "Multi-target incretin-based therapeutics: The rise of dual a..." RPEP-14732. Retrieved from https://rethinkpeptides.com/research/alavi-2026-multitarget-incretinbased-therapeutics-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.